Citations (87)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Pavel Klener. (2020) Mantle cell lymphoma: insights into therapeutic targets at the preclinical level. Expert Opinion on Therapeutic Targets 24:10, pages 1029-1045.
Read now
Read now
Benedito A Carneiro, Jessica K Altman, Jason B Kaplan, Gert Ossenkoppele, Ronan Swords, Leonidas C Platanias & Francis J Giles. (2015) Targeted therapy of acute myeloid leukemia. Expert Review of Anticancer Therapy 15:4, pages 399-413.
Read now
Read now
Eric D. Hsi & Peter Martin. (2014) Indolent mantle cell lymphoma. Leukemia & Lymphoma 55:4, pages 761-767.
Read now
Read now
David Salek, Pavla Vesela, Ludmila Boudova, Andrea Janikova, Pavel Klener, Samuel Vokurka, Milada Jankovska, Robert Pytlik, David Belada, Jan Pirnos, Mojmir Moulis, Roman Kodet, Michal Michal, Eva Janousova, Jan Muzik, Jiri Mayer & Marek Trněný. (2014) Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database. Leukemia & Lymphoma 55:4, pages 802-810.
Read now
Read now
Sailay Siddiqi & Mark A Sussman. (2013) Cell and gene therapy for severe heart failure patients: The time and place for Pim-1 kinase. Expert Review of Cardiovascular Therapy 11:8, pages 949-957.
Read now
Read now
Anna Lena Merkel, Eric Meggers & Matthias Ocker. (2012) PIM1 kinase as a target for cancer therapy. Expert Opinion on Investigational Drugs 21:4, pages 425-436.
Read now
Read now
Yesid Alvarado, Francis J Giles & Ronan T Swords. (2012) The PIM kinases in hematological cancers. Expert Review of Hematology 5:1, pages 81-96.
Read now
Read now
Katrin Tiemann, Jessica V. Alluin, Anja Honegger, Pritsana Chomchan, Shikha Gaur, Yen Yun, Stephen J. Forman, John J. Rossi & Robert W. Chen. (2011) Small interfering RNAs targeting cyclin D1 and cyclin D2 enhance the cytotoxicity of chemotherapeutic agents in mantle cell lymphoma cell lines. Leukemia & Lymphoma 52:11, pages 2148-2154.
Read now
Read now
Satish Shanbhag, Mitchell R Smith & Robert VB Emmons. (2010) Tackling mantle cell lymphoma (MCL): Potential benefit of allogeneic stem cell transplantation. Stem Cells and Cloning: Advances and Applications 3, pages 93-102.
Read now
Read now
André Goy, Steven H. Bernstein, Alice Mcdonald, Michael D. Pickard, Hongliang Shi, Mark D. Fleming, Barb Bryant, William Trepicchio, Richard I. Fisher, Anthony L. Boral & George Mulligan. (2010) Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial. Leukemia & Lymphoma 51:7, pages 1269-1277.
Read now
Read now
Stephen D. Smith & John W. Sweetenham. (2010) Intensive therapies for mantle cell lymphoma: time for a disease-specific approach?. Leukemia & Lymphoma 51:3, pages 357-359.
Read now
Read now
Michael E. Williams, Martin H. Dreyling, Brad S. Kahl, John P. Leonard, Owen A. O'connor, Oliver W. Press & Wyndham H. Wilson. (2010) Mantle cell lymphoma: Report of the 2009 Mantle Cell Lymphoma Consortium Workshop. Leukemia & Lymphoma 51:3, pages 390-398.
Read now
Read now
Articles from other publishers (75)
Ying Jin, Cheng Wang, Li Yang, William C.S. Cho & Guoqi Song. 2024. Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal. Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal
77
102
.
Jay Jiyong Kwak, Kwang Seob Lee, Junwon Lee, Yong Joon Kim, Eun Young Choi, Suk Ho Byeon, Won Seok Chang, Yu Ri Kim, Jin Seok Kim, Saeam Shin, Seung-Tae Lee, Sung Soo Kim & Christopher Seungkyu Lee. (2023) Next-Generation Sequencing of Vitreoretinal Lymphoma by Vitreous Liquid Biopsy: Diagnostic Potential and Genotype/Phenotype Correlation. Investigative Opthalmology & Visual Science 64:14, pages 27.
Crossref
Crossref
Manish R. Patel, William Donnellan, Michael Byrne, Adam S. Asch, Amer M. Zeidan, Maria R. Baer, Amir T. Fathi, Andrew T. Kuykendall, Fred Zheng, Chris Walker, Lulu Cheng, Cindy Marando & Michael R. Savona. (2023) Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies. Clinical Lymphoma Myeloma and Leukemia 23:9, pages 674-686.
Crossref
Crossref
Josh T. Coats, Sudhir Tauro & Calum Sutherland. (2023) Elraglusib (formerly 9-ING-41) possesses potent anti-lymphoma properties which cannot be attributed to GSK3 inhibition. Cell Communication and Signaling 21:1.
Crossref
Crossref
Pablo Mozas, Cristina López, Marta Grau, Ferran Nadeu, Guillem Clot, Sara Valle, Marta Kulis, Alba Navarro, Joan Enric Ramis‐Zaldivar, Blanca González‐Farré, Alfredo Rivas‐Delgado, Andrea Rivero, Gerard Frigola, Olga Balagué, Eva Giné, Julio Delgado, Neus Villamor, Estella Matutes, Laura Magnano, Ramón García‐Sanz, Sarah Huet, Robert B. Russell, Elías Campo, Armando López‐Guillermo & Sílvia Beà. (2023) Genomic landscape of follicular lymphoma across a wide spectrum of clinical behaviors. Hematological Oncology.
Crossref
Crossref
Marcia Bellon & Christophe Nicot. (2023) Targeting Pim kinases in hematological cancers: molecular and clinical review. Molecular Cancer 22:1.
Crossref
Crossref
Lindsay Hammons & Timothy S. Fenske. (2022) Treatment of Mantle Cell Lymphoma in the Frontline Setting: Are We Ready for a Risk-Adapted Approach?. Journal of Personalized Medicine 12:7, pages 1134.
Crossref
Crossref
Masamitsu Yanada & Kazuhito Yamamoto. (2022) Hematopoietic cell transplantation for mantle cell lymphoma. International Journal of Hematology 115:3, pages 301-309.
Crossref
Crossref
Aanchal Rathi, Dhiraj Kumar, Gulam Mustafa Hasan, Mohammad Mahfuzul Haque & Md Imtaiyaz Hassan. (2021) Therapeutic targeting of PIM KINASE signaling in cancer therapy: Structural and clinical prospects. Biochimica et Biophysica Acta (BBA) - General Subjects 1865:11, pages 129995.
Crossref
Crossref
Suvankar Banerjee, Sk. Abdul Amin & Tarun Jha. (2021) Therapies of Hematological Malignancies: An Overview of the Potential Targets and Their Inhibitors. Current Chemical Biology 15:1, pages 19-49.
Crossref
Crossref
Ashish Bahuguna, Ashutosh Singh, Prateek Kumar, Divya Dhasmana, Venkata Krishnan & Neha Garg. (2020) Bisindolemethane derivatives as highly potent anticancer agents: Synthesis, medicinal activity evaluation, cell-based compound discovery, and computational target predictions. Computers in Biology and Medicine 116, pages 103574.
Crossref
Crossref
Fabiola Cervantes-Gomez, Christine M. Stellrecht, Mary L. Ayres, Michael J. Keating, William G. Wierda & Varsha Gandhi. (2019) PIM kinase inhibitor, AZD1208, inhibits protein translation and induces autophagy in primary chronic lymphocytic leukemia cells. Oncotarget 10:29, pages 2793-2809.
Crossref
Crossref
Lianjing Cao, Fan Wang, Shouying Li, Xinyue Wang, Dingzhi Huang & Richeng Jiang. (2019) PIM1 kinase promotes cell proliferation, metastasis and tumor growth of lung adenocarcinoma by potentiating the c-MET signaling pathway. Cancer Letters 444, pages 116-126.
Crossref
Crossref
Mukesh Verma, Debmalya Barh & Syed Shah Hassan. 2019. Genomics and Clinical Diagnostics. Genomics and Clinical Diagnostics
494
530
.
Amos Burke, Joerg Krueger & Birte Wistinghausen. 2019. Non-Hodgkin's Lymphoma in Childhood and Adolescence. Non-Hodgkin's Lymphoma in Childhood and Adolescence
315
335
.
Jonathan L. Myles, Mark Synovec, Todd Klemp & William S. Black-Schaffer. (2018) Current CPT Coding and Payment Policy Implications for Immunohistology Services. Advances in Anatomic Pathology 25:6, pages 430-433.
Crossref
Crossref
Yangying Zhou, Wei Liu, Zhijie Xu, Hong Zhu, Desheng Xiao, Weiping Su, Ruolan Zeng, Yuhua Feng, Yumei Duan, Jianhua Zhou & Meizuo Zhong. (2018) Analysis of Genomic Alteration in Primary Central Nervous System Lymphoma and the Expression of Some Related Genes. Neoplasia 20:10, pages 1059-1069.
Crossref
Crossref
Xixi Xiang, Di Yuan, Yao Liu, Jiali Li, Qin Wen, Peiyan Kong, Lei Gao, Cheng Zhang, Li Gao, Xiangui Peng & Xi Zhang. (2018) PIM1 overexpression in T-cell lymphomas protects tumor cells from apoptosis and confers doxorubicin resistance by upregulating c-myc expression. Acta Biochimica et Biophysica Sinica 50:8, pages 800-806.
Crossref
Crossref
Holly Koblish, Yun-long Li, Niu Shin, Leslie Hall, Qian Wang, Kathy Wang, Maryanne Covington, Cindy Marando, Kevin Bowman, Jason Boer, Krista Burke, Richard Wynn, Alex Margulis, Gary W. Reuther, Que T. Lambert, Valerie Dostalik Roman, Ke Zhang, Hao Feng, Chu-Biao Xue, Sharon Diamond, Greg Hollis, Swamy Yeleswaram, Wenqing Yao, Reid Huber, Kris Vaddi & Peggy Scherle. (2018) Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies. PLOS ONE 13:6, pages e0199108.
Crossref
Crossref
Bruno Oyallon, Marie Brachet-Botineau, Cédric Logé, Pascal Bonnet, Mohamed Souab, Thomas Robert, Sandrine Ruchaud, Stéphane Bach, Pascal Berthelot, Fabrice Gouilleux, Marie-Claude Viaud-Massuard & Caroline Denevault-Sabourin. (2018) Structure-based design of novel quinoxaline-2-carboxylic acids and analogues as Pim-1 inhibitors. European Journal of Medicinal Chemistry 154, pages 101-109.
Crossref
Crossref
Şule Öztürk Sari, Orhun Çiğ Taşkin, Gülçin Yegen, Yasemin Özlük & Mine Güllüoğlu. (2018) Ki67 Scoring in Pancreatic Neuroendocrine Tumors By a New Method. Applied Immunohistochemistry & Molecular Morphology 26:4, pages 283-287.
Crossref
Crossref
Von G. Samedi & Qian-Yun Zhang. 2018. Atlas of Non-Gynecologic Cytology. Atlas of Non-Gynecologic Cytology
259
288
.
Manuel-Pedro Jiménez-García, Antonio Lucena-Cacace, María-José Robles-Frías, Irene Ferrer, Maja Narlik-Grassow, Carmen Blanco-Aparicio & Amancio Carnero. (2017) Inflammation and stem markers association to PIM1/PIM2 kinase-induced tumors in breast and uterus. Oncotarget 8:35, pages 58872-58886.
Crossref
Crossref
Sathish K.R. Padi, Libia A. Luevano, Ningfei An, Ritu Pandey, Neha Singh, Jin H. Song, Jon C. Aster, Xue-Zhong Yu, Shikhar Mehrotra & Andrew S. Kraft. (2017) Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset. Oncotarget 8:18, pages 30199-30216.
Crossref
Crossref
Jonathon B. CohenJasmine M. ZainBrad S. Kahl. (2017) Current Approaches to Mantle Cell Lymphoma: Diagnosis, Prognosis, and Therapies. American Society of Clinical Oncology Educational Book:37, pages 512-525.
Crossref
Crossref
Xiao-xu Wang, Jue Liu, Yi-min Tang, Liang Hong, Zhi Zeng & Guang-hua Tan. (2017) MicroRNA-638 inhibits cell proliferation by targeting suppress PIM1 expression in human osteosarcoma. Tumor Biology 37:12, pages 16367-16375.
Crossref
Crossref
Tara L. Peters, Lingxiao Li, Ana A. Tula-Sanchez, Praechompoo Pongtornpipat & Jonathan H. Schatz. (2016) Control of translational activation by PIM kinase in activated B-cell diffuse large B-cell lymphoma confers sensitivity to inhibition by PIM447. Oncotarget 7:39, pages 63362-63373.
Crossref
Crossref
Shahram Kordasti, Benedetta CostantiniThomas SeidlPilar Perez AbellanMarc Martinez LlordellaDonal McLornanKirsten E. DigginsAustin KulasekararajCinzia BenfattoXingmin Feng, Alexander SmithSyed A. MianRossella Melchiotti, Emanuele de Rinaldis, Richard Ellis, Nedyalko Petrov, Giovanni A. M. PovoleriSun Sook ChungN. Shaun B. ThomasFarzin FarzanehJonathan M. IrishSusanne Heck, Neal S. Young, Judith C. W. MarshGhulam J. Mufti. (2016) Deep phenotyping of Tregs identifies an immune signature for idiopathic aplastic anemia and predicts response to treatment. Blood 128:9, pages 1193-1205.
Crossref
Crossref
Renukadevi Patil, Siddappa A Patil, Kenneth D Beaman & Shivaputra A Patil. (2016) Indole molecules as inhibitors of tubulin polymerization: potential new anticancer agents, an update (2013–2015). Future Medicinal Chemistry 8:11, pages 1291-1316.
Crossref
Crossref
Diede Brunen, María José García-Barchino, Disha Malani, Noorjahan Jagalur Basheer, Cor Lieftink, Roderick L. Beijersbergen, Astrid Murumägi, Kimmo Porkka, Maija Wolf, C. Michel Zwaan, Maarten Fornerod, Olli Kallioniemi, José Ángel Martínez-Climent & René Bernards. (2016) Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling. Oncotarget 7:25, pages 37407-37419.
Crossref
Crossref
F F Blanco, M Jimbo, J Wulfkuhle, I Gallagher, J Deng, L Enyenihi, N Meisner-Kober, E Londin, I Rigoutsos, J A Sawicki, M V Risbud, A K Witkiewicz, P A McCue, W Jiang, H Rui, C J Yeo, E Petricoin, J M Winter & J R Brody. (2015) The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells. Oncogene 35:19, pages 2529-2541.
Crossref
Crossref
Hang Wang, Miqing Yang, Ling Lin, Hongzhen Ren, Chaotong Lin, Suling Lin, Guoying Shen, Binfeng Ji & Chun Meng. (2015) HepG2 cells acquire stem cell-like characteristics after immune cell stimulation. Cellular Oncology 39:1, pages 35-45.
Crossref
Crossref
Tae-Dong JeongHyun-Sook ChiMin-Sun KimSeongsoo JangChan-Jeoung ParkJoo Ryung Huh. (2016) Prognostic relevance of the Ki-67 proliferation index in patients with mantle cell lymphoma. Blood Research 51:2, pages 127.
Crossref
Crossref
Rajathees Rajaratnam, Elisabeth K. Martin, Markus Dörr, Klaus Harms, Angela CasiniEric Meggers. (2015) Correlation between the Stereochemistry and Bioactivity in Octahedral Rhodium Prolinato Complexes. Inorganic Chemistry 54:16, pages 8111-8120.
Crossref
Crossref
Yngvild N Blaker, Marianne Brodtkorb, John Maddison, Tarjei S Hveem, John Arne Nesheim, Hans Martin Mohn, Arne Kolstad, Christian H Geisler, Knut Liestøl, Erlend B Smeland, Harald Holte, Jan Delabie & Håvard Danielsen. (2015) Computerized image analysis of the Ki-67 proliferation index in mantle cell lymphoma. Histopathology 67:1, pages 62-69.
Crossref
Crossref
Jonathon B. Cohen, Amy S. Ruppert, Nyla A. Heerema, Leslie A. Andritsos, Jeffrey A. Jones, Pierluigi Porcu, Robert Baiocchi, Beth A. Christian, John C. Byrd, Joseph Flynn, Sam Penza, Steven M. Devine & Kristie A. Blum. (2015) Complex Karyotype Is Associated With Aggressive Disease and Shortened Progression-Free Survival in Patients With Newly Diagnosed Mantle Cell Lymphoma. Clinical Lymphoma Myeloma and Leukemia 15:5, pages 278-285.e1.
Crossref
Crossref
Jonathon B. Cohen, Linda J. Burns & Veronika Bachanova. (2015) Role of allogeneic stem cell transplantation in mantle cell lymphoma. European Journal of Haematology 94:4, pages 290-297.
Crossref
Crossref
Yong Xu, Benjamin G. Brenning, Steven G. Kultgen, Jason M. Foulks, Adrianne Clifford, Shuping Lai, Ashley Chan, Shannon Merx, Michael V. McCullar, Steven B. Kanner & Koc-Kan Ho. (2014)
Synthesis and Biological Evaluation of Pyrazolo[1,5-
a
]pyrimidine Compounds as Potent and Selective Pim-1 Inhibitors
. ACS Medicinal Chemistry Letters 6:1, pages 63-67.
Crossref
Crossref
Hong-bao Sun, Xiao-yan Wang, Guo-bo Li, Li-dan Zhang, Jie Liu & Li-feng Zhao. (2015) Design, synthesis and biological evaluation of novel C3-functionalized oxindoles as potential Pim-1 kinase inhibitors. RSC Advances 5:37, pages 29456-29466.
Crossref
Crossref
Patrizia Mondello, Salvatore Cuzzocrea & Michael Mian. (2014) Pim kinases in hematological malignancies: where are we now and where are we going?. Journal of Hematology & Oncology 7:1.
Crossref
Crossref
Xin He, Zhigang Chen, Tao Fu, Xueli Jin, Teng Yu, Yun Liang, Xiaoying Zhao & Liansheng Huang. (2014) Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis. BMC Cancer 14:1.
Crossref
Crossref
Hiroaki Taniguchi, Hiroo Hasegawa, Daisuke Sasaki, Koji Ando, Yasushi Sawayama, Daisuke Imanishi, Jun Taguchi, Yoshitaka Imaizumi, Tomoko Hata, Kunihiro Tsukasaki, Naoki Uno, Yoshitomo Morinaga, Katsunori Yanagihara & Yasushi Miyazaki. (2014)
Heat shock protein 90 inhibitor
NVP
‐
AUY
922 exerts potent activity against adult T‐cell leukemia–lymphoma cells
. Cancer Science 105:12, pages 1601-1608.
Crossref
Crossref
Vijaya Raj Bhatt & Julie M. Vose. (2014) Hematopoietic Stem Cell Transplantation for Non-Hodgkin Lymphoma. Hematology/Oncology Clinics of North America 28:6, pages 1073-1095.
Crossref
Crossref
Roberta Zappasodi, Alessandra Cavanè, Marilena V. Iorio, Monica Tortoreto, Carla Guarnotta, Giusi Ruggiero, Claudia Piovan, Michele Magni, Nadia Zaffaroni, Elda Tagliabue, Carlo M. Croce, Franco Zunino, Alessandro M. Gianni & Massimo Di Nicola. (2014) Pleiotropic antitumor effects of the pan-HDAC inhibitor ITF2357 against c-Myc-overexpressing human B-cell non-Hodgkin lymphomas. International Journal of Cancer 135:9, pages 2034-2045.
Crossref
Crossref
Shuvomoy Banerjee, Jie Lu, Qiliang Cai, Zhiguo Sun, Hem Chandra Jha & Erle S. Robertson. (2014) EBNA3C Augments Pim-1 Mediated Phosphorylation and Degradation of p21 to Promote B-Cell Proliferation. PLoS Pathogens 10:8, pages e1004304.
Crossref
Crossref
Michael E. Williams, L. Kyle Brett, Martin Dreyling, German Ott & Eric D. Hsi. 2014. Rare Lymphomas. Rare Lymphomas
277
302
.
Maja Narlik-Grassow, Carmen Blanco-Aparicio & Amancio Carnero. (2014) The PIM Family of Serine/Threonine Kinases in Cancer. Medicinal Research Reviews 34:1, pages 136-159.
Crossref
Crossref
J B Cohen, N C Hall, A S Ruppert, J A Jones, P Porcu, R Baiocchi, B A Christian, S Penza, D M Benson, J Flynn, L A Andritsos, S M Devine & K A Blum. (2013) Association of pre-transplantation positron emission tomography/computed tomography and outcome in mantle cell lymphoma. Bone Marrow Transplantation 48:9, pages 1212-1217.
Crossref
Crossref
Qingshan Yang, Lisa S. Chen, Sattva S. Neelapu & Varsha Gandhi. (2013) Combination of Pim Kinase Inhibitor SGI-1776 and Bendamustine in B-Cell Lymphoma. Clinical Lymphoma Myeloma and Leukemia 13, pages S355-S362.
Crossref
Crossref
Peter Kristian Rasmussen. (2013) Diffuse large B‐cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: An investigation of clinical and histopathological features. Acta Ophthalmologica 91:thesis5, pages 1-27.
Crossref
Crossref
Bo Cen, Sandeep Mahajan, Wenxue Wang & Andrew S. Kraft. (2013) Elevation of Receptor Tyrosine Kinases by Small Molecule AKT Inhibitors in Prostate Cancer Is Mediated by Pim-1. Cancer Research 73:11, pages 3402-3411.
Crossref
Crossref
Marjo Malinen, Tiina J??skel?inen, Mikko Pelkonen, Sami Heikkinen, Sami V?is?nen, Veli-Matti Kosma, Kaisa Nieminen, Arto Mannermaa & Jorma J. Palvimo. (2013) Proto-oncogene PIM-1 is a novel estrogen receptor target associating with high grade breast tumors. Molecular and Cellular Endocrinology 365:2, pages 270-276.
Crossref
Crossref
Diana O. Treaba & Diana O. Treaba. 2013. Non-Hodgkin Lymphoma. Non-Hodgkin Lymphoma
101
139
.
Qingshan Yang, Lisa S. ChenSattva S. NeelapuRoberto N. Miranda, L. Jeffrey Medeiros & Varsha Gandhi. (2012) Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma. Blood 120:17, pages 3491-3500.
Crossref
Crossref
Gustavo Saluste, Maria I. Albarran, Rosa M. Alvarez, Obdulia Rabal, Miguel Angel Ortega, Carmen Blanco, Guido Kurz, Antonio Salgado, Paolo Pevarello, James R. Bischoff, Joaquin Pastor & Julen Oyarzabal. (2012) Fragment-Hopping-Based Discovery of a Novel Chemical Series of Proto-Oncogene PIM-1 Kinase Inhibitors. PLoS ONE 7:10, pages e45964.
Crossref
Crossref
L Brault, T Menter, E C Obermann, S Knapp, S Thommen, J Schwaller & A Tzankov. (2012) PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma. British Journal of Cancer 107:3, pages 491-500.
Crossref
Crossref
Peter Martin, Mitchell Smith & Brian Till. (2012) Management of mantle cell lymphoma in the elderly. Best Practice & Research Clinical Haematology 25:2, pages 221-231.
Crossref
Crossref
Cristina Gómez-AbadHelena PisoneroCarmen Blanco-Aparicio, Giovanna RoncadorAlberto González-Menchén, Jose A. Martinez-Climent, Eva MataMaría Elena RodríguezGuillermo Muñoz-GonzálezMargarita Sánchez-BeatoJuan F. Leal, James R. Bischoff & Miguel A. Piris. (2011) PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma. Blood 118:20, pages 5517-5527.
Crossref
Crossref
Jonathan H. Schatz. (2011) Targeting the PI3K/AKT/mTOR Pathway in Non-Hodgkin’s Lymphoma: Results, Biology, and Development Strategies. Current Oncology Reports 13:5, pages 398-406.
Crossref
Crossref
Jonathan H. Schatz, Elisa Oricchio, Andrew L. Wolfe, Man Jiang, Irina Linkov, Jocelyn Maragulia, Weiji Shi, Zhigang Zhang, Vinagolu K. Rajasekhar, Nen C. Pagano, John A. PorcoJr.Jr., Julie Teruya-Feldstein, Neal Rosen, Andrew D. Zelenetz, Jerry Pelletier & Hans-Guido Wendel. (2011) Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma. Journal of Experimental Medicine 208:9, pages 1799-1807.
Crossref
Crossref
Linus Plym Forshell, Yongmei Li, Tacha Zi Plym Forshell, Martina Rudelius, Lisa Nilsson, Ulrich Keller & Jonas Nilsson. (2011) The direct Myc target Pim3 cooperates with other Pim kinases in supporting viability of Myc-induced B-cell lymphomas. Oncotarget 2:6, pages 448-460.
Crossref
Crossref
Martijn C. Nawijn, Andrej Alendar & Anton Berns. (2010) For better or for worse: the role of Pim oncogenes in tumorigenesis. Nature Reviews Cancer 11:1, pages 23-34.
Crossref
Crossref
Carmen Blanco-Aparicio, Ana María García Collazo, Julen Oyarzabal, Juan F. Leal, María Isabel Albarán, Francisco Ramos Lima, Belén Pequeño, Nuria Ajenjo, Mercedes Becerra, Patricia Alfonso, María Isabel Reymundo, Irene Palacios, Genoveva Mateos, Helena Quiñones, Ana Corrionero, Amancio Carnero, Paolo Pevarello, Ana Rodríguez Lopez, Jesús Fominaya, Joaquín Pastor & James R. Bischoff. (2011) Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition. Cancer Letters 300:2, pages 145-153.
Crossref
Crossref
Andre Goy. 2011. Management of Hematologic Malignancies. Management of Hematologic Malignancies
308
337
.
Nancy S Magnuson, Zeping Wang, Gang Ding & Raymond Reeves. (2010) Why target PIM1 for cancer diagnosis and treatment?. Future Oncology 6:9, pages 1461-1478.
Crossref
Crossref
Michele Roullet & Adam Bagg. (2010) The Basis and Rational Use of Molecular Genetic Testing in Mature B-cell Lymphomas. Advances in Anatomic Pathology 17:5, pages 333-358.
Crossref
Crossref
Marina Zemskova, Michael B. Lilly, Ying-Wei Lin, Jin H. Song & Andrew S. Kraft. (2010) p53-Dependent Induction of Prostate Cancer Cell Senescence by the PIM1 Protein Kinase. Molecular Cancer Research 8:8, pages 1126-1141.
Crossref
Crossref
Fabio Facchetti & Marco Ungari. (2010) Advances in the Molecular Morphology of Hematopathology. International Journal of Surgical Pathology 18:3_suppl, pages 128-132.
Crossref
Crossref
Christian H. GeislerArne KolstadAnna LaurellRiikka RätyMats JerkemanMikael ErikssonMarie NordströmEva KimbyAnne Marie BoesenHerman Nilsson-Ehle, Outi Kuittinen, Grete F. LauritzsenElisabeth RalfkiærMats EhingerChrister SundströmJan DelabieMarja-Liisa Karjalainen-LindsbergPeter BrownErkki Elonen. (2010) The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood 115:8, pages 1530-1533.
Crossref
Crossref
Ying-Wei LinZanna M. BeharryElizabeth G. HillJin H. SongWenxue WangZuping XiaZhenhua ZhangPeter D. AplanJon C. Aster, Charles D. SmithAndrew S. Kraft. (2010) A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma. Blood 115:4, pages 824-833.
Crossref
Crossref
R. Schaffel, C.V. Hedvat, J. Teruya-Feldstein, D. Persky, J. Maragulia, D. Lin, C.S. Portlock, C.H. Moskowitz & A.D. Zelenetz. (2010) Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma. Annals of Oncology 21:1, pages 133-139.
Crossref
Crossref
James T. Edinger, Beth Z. Clark, Brian E. Pucevich, Larisa J. Geskin & Steven H. Swerdlow. (2009) CD30 Expression and Proliferative Fraction in Nontransformed Mycosis Fungoides. American Journal of Surgical Pathology 33:12, pages 1860-1868.
Crossref
Crossref
George Apostolou, Nikolaos Apostolou, Paschalis Chatzipantelis & Maria Biteli. (2009) Spiradenocylindrocarcinoma. Report of a Case With a Low-Grade Component of Spiradenocarcinoma and an Immunohistochemical Study. The American Journal of Dermatopathology 31:6, pages 594-598.
Crossref
Crossref
Eric D. Hsi. (2009) The Role of Biomarkers in the Management of Patients with Lymphoma: Promise Versus Reality. Clinical Lymphoma and Myeloma 9:2, pages 121-123.
Crossref
Crossref
J. Han van Krieken. (2009) New developments in the pathology of malignant lymphoma: a review of the literature published from August to December 2008. Journal of Hematopathology 2:1, pages 50-61.
Crossref
Crossref